Cargando…
Blood lactate in mild and moderate ARDS secondary to SARS COV 2
BACKGROUND AND OBJECTIVES: Elevated blood lactate levels are associated with poor outcome in several critical conditions. Patients with SARS-CoV-2 rarely develop hyperlactatemia. The purpose of this study is to evaluate the trend of lactatemia in patients affected by mild/moderate SARS-Co V-2-ARDS a...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869639/ https://www.ncbi.nlm.nih.gov/pubmed/36731159 http://dx.doi.org/10.1016/j.ajem.2023.01.032 |
_version_ | 1784876810695081984 |
---|---|
author | Pagano, A. Porta, G. Bosso, G. Allegorico, E. Serra, C. Mercurio, V. Sansone, G. Orefice, S. Numis, F.G. |
author_facet | Pagano, A. Porta, G. Bosso, G. Allegorico, E. Serra, C. Mercurio, V. Sansone, G. Orefice, S. Numis, F.G. |
author_sort | Pagano, A. |
collection | PubMed |
description | BACKGROUND AND OBJECTIVES: Elevated blood lactate levels are associated with poor outcome in several critical conditions. Patients with SARS-CoV-2 rarely develop hyperlactatemia. The purpose of this study is to evaluate the trend of lactatemia in patients affected by mild/moderate SARS-Co V-2-ARDS and if it affected prognosis. METHODS: We analyzed blood lactate levels in thirty-eight patients with severe SARS-CoV-2 infection admitted to COVID Care Unit of Santa Maria delle Grazie Hospital, Pozzuoli. RESULTS: Twenty patients survived and were discharged at home and 18 patients died. Despite severe hypoxia that affected all patients enrolled, T0 lactate was within normal values. All survivors showed a significant increase in lactate concentration the day prior to clinical improvement. In not-survivors levels of lactate did not increase significantly. CONCLUSION: In our study, patients who survive SARS CoV-2 ARDS have a fleeting increase in lactate, which precedes clinical improvement by one day. |
format | Online Article Text |
id | pubmed-9869639 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98696392023-01-23 Blood lactate in mild and moderate ARDS secondary to SARS COV 2 Pagano, A. Porta, G. Bosso, G. Allegorico, E. Serra, C. Mercurio, V. Sansone, G. Orefice, S. Numis, F.G. Am J Emerg Med Article BACKGROUND AND OBJECTIVES: Elevated blood lactate levels are associated with poor outcome in several critical conditions. Patients with SARS-CoV-2 rarely develop hyperlactatemia. The purpose of this study is to evaluate the trend of lactatemia in patients affected by mild/moderate SARS-Co V-2-ARDS and if it affected prognosis. METHODS: We analyzed blood lactate levels in thirty-eight patients with severe SARS-CoV-2 infection admitted to COVID Care Unit of Santa Maria delle Grazie Hospital, Pozzuoli. RESULTS: Twenty patients survived and were discharged at home and 18 patients died. Despite severe hypoxia that affected all patients enrolled, T0 lactate was within normal values. All survivors showed a significant increase in lactate concentration the day prior to clinical improvement. In not-survivors levels of lactate did not increase significantly. CONCLUSION: In our study, patients who survive SARS CoV-2 ARDS have a fleeting increase in lactate, which precedes clinical improvement by one day. Elsevier Inc. 2023-04 2023-01-23 /pmc/articles/PMC9869639/ /pubmed/36731159 http://dx.doi.org/10.1016/j.ajem.2023.01.032 Text en © 2023 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Pagano, A. Porta, G. Bosso, G. Allegorico, E. Serra, C. Mercurio, V. Sansone, G. Orefice, S. Numis, F.G. Blood lactate in mild and moderate ARDS secondary to SARS COV 2 |
title | Blood lactate in mild and moderate ARDS secondary to SARS COV 2 |
title_full | Blood lactate in mild and moderate ARDS secondary to SARS COV 2 |
title_fullStr | Blood lactate in mild and moderate ARDS secondary to SARS COV 2 |
title_full_unstemmed | Blood lactate in mild and moderate ARDS secondary to SARS COV 2 |
title_short | Blood lactate in mild and moderate ARDS secondary to SARS COV 2 |
title_sort | blood lactate in mild and moderate ards secondary to sars cov 2 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869639/ https://www.ncbi.nlm.nih.gov/pubmed/36731159 http://dx.doi.org/10.1016/j.ajem.2023.01.032 |
work_keys_str_mv | AT paganoa bloodlactateinmildandmoderateardssecondarytosarscov2 AT portag bloodlactateinmildandmoderateardssecondarytosarscov2 AT bossog bloodlactateinmildandmoderateardssecondarytosarscov2 AT allegoricoe bloodlactateinmildandmoderateardssecondarytosarscov2 AT serrac bloodlactateinmildandmoderateardssecondarytosarscov2 AT mercuriov bloodlactateinmildandmoderateardssecondarytosarscov2 AT sansoneg bloodlactateinmildandmoderateardssecondarytosarscov2 AT orefices bloodlactateinmildandmoderateardssecondarytosarscov2 AT numisfg bloodlactateinmildandmoderateardssecondarytosarscov2 |